PE20010665A1 - A PHARMACEUTICAL COMPOSITION OF DROSPIRENONE AND ETHINYLESTRADIOL TO BE USED AS A CONTRACEPTIVE - Google Patents
A PHARMACEUTICAL COMPOSITION OF DROSPIRENONE AND ETHINYLESTRADIOL TO BE USED AS A CONTRACEPTIVEInfo
- Publication number
- PE20010665A1 PE20010665A1 PE2000000895A PE0008952000A PE20010665A1 PE 20010665 A1 PE20010665 A1 PE 20010665A1 PE 2000000895 A PE2000000895 A PE 2000000895A PE 0008952000 A PE0008952000 A PE 0008952000A PE 20010665 A1 PE20010665 A1 PE 20010665A1
- Authority
- PE
- Peru
- Prior art keywords
- ethinylestradiol
- drospirenone
- pharmaceutical composition
- composition
- contraceptive
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003433 contraceptive agent Substances 0.000 title 1
- 230000002254 contraceptive effect Effects 0.000 title 1
- 229940007690 drospirenone and ethinylestradiol Drugs 0.000 title 1
- 239000013543 active substance Substances 0.000 abstract 3
- 229960002568 ethinylestradiol Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 abstract 1
- 208000002874 Acne Vulgaris Diseases 0.000 abstract 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 abstract 1
- 206010000496 acne Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 abstract 1
- 229960004845 drospirenone Drugs 0.000 abstract 1
- 230000016087 ovulation Effects 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a)UN AGENTE ACTIVO 6ß,7ß; 15ß,16ß-DIMETILEN-3-OXO-17O-PREGN-4-EN-21, 17-CARBOLACTONA (DROSPIRENONA, UTILIZANDOSE 2mg A 4mg; b)17O-ETINILESTRADIOL (ETINILESTRADIOL) UTILIZANDOSE 0,01 mg A 0,05mg; c)EXCIPIENTES QUE PROMUEVEN LA DISOLUCION RAPIDA DE LOS AGENTES ACTIVOS; LA COMPOSICION SE CARACTERIZA PORQUE LOS AGENTES SE ENCUENTRAN EN FORMA MICRONIZADA O PULVERIZADA EN UNA SOLUCION SOBRE PARTICULAS DE SOPORTE INERTE, EL 70% DE LAS SUSTANCIAS ACTIVAS ES LIBERADA DENTRO DE LOS 30 MINUTOS DESDE LA ADMINISTRACION DE LA MISMA. LA COMPOSICION PUEDE SER UTIL PARA INHIBIR LA OVULACION, TRATAR TRASTORNOS INDUCIDOS POR ANDROGENOS COMO ACNEIT REFERS TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES: a) AN ACTIVE AGENT 6ß, 7ß; 15ß, 16ß-DIMETHYLENE-3-OXO-17O-PREGN-4-EN-21, 17-CARBOLACTONE (DROSPIRENONE, USING 2mg TO 4mg; b) 17O-ETHINYLESTRADIOL (ETHINYLESTRADIOL) USING 0.01mg TO 0.05mg; c) EXCIPIENTS THAT PROMOTE THE RAPID DISSOLUTION OF THE ACTIVE AGENTS; THE COMPOSITION IS CHARACTERIZED BECAUSE THE AGENTS ARE IN MICRONIZED OR POWDERED FORM IN A SOLUTION ON INERT SUPPORT PARTICLES, 70% OF THE ACTIVE SUBSTANCES ARE RELEASED WITHIN 30 MINUTES FROM THE ADMINISTRATION OF THE SAME. THE COMPOSITION MAY BE USEFUL TO INHIBIT OVULATION, TREAT ANDROGEN-INDUCED DISORDERS SUCH AS ACNE
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99202826 | 1999-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010665A1 true PE20010665A1 (en) | 2001-06-19 |
Family
ID=8240592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000000895A PE20010665A1 (en) | 1999-08-31 | 2000-08-31 | A PHARMACEUTICAL COMPOSITION OF DROSPIRENONE AND ETHINYLESTRADIOL TO BE USED AS A CONTRACEPTIVE |
Country Status (6)
| Country | Link |
|---|---|
| CN (1) | CN1879632A (en) |
| AR (2) | AR025443A1 (en) |
| CO (1) | CO5200771A1 (en) |
| EC (1) | ECSP003721A (en) |
| PE (1) | PE20010665A1 (en) |
| ZA (2) | ZA200201668B (en) |
-
2000
- 2000-08-30 AR ARP000104515A patent/AR025443A1/en not_active Application Discontinuation
- 2000-08-31 PE PE2000000895A patent/PE20010665A1/en not_active IP Right Cessation
- 2000-08-31 CO CO00065489A patent/CO5200771A1/en not_active Application Discontinuation
- 2000-08-31 CN CNA2005100992135A patent/CN1879632A/en active Pending
- 2000-10-18 EC EC2000003721A patent/ECSP003721A/en unknown
-
2002
- 2002-02-27 ZA ZA200201668A patent/ZA200201668B/en unknown
-
2004
- 2004-03-05 AR ARP040100696A patent/AR043470A2/en not_active Application Discontinuation
-
2005
- 2005-05-25 ZA ZA200404083A patent/ZA200404083B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR025443A1 (en) | 2002-11-27 |
| ZA200201668B (en) | 2004-06-24 |
| ECSP003721A (en) | 2002-05-23 |
| CO5200771A1 (en) | 2002-09-27 |
| AR043470A2 (en) | 2005-07-27 |
| CN1879632A (en) | 2006-12-20 |
| ZA200404083B (en) | 2006-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MEP38008A (en) | Drospirenone for hormone replacement therapy | |
| BR0014159A (en) | Pharmaceutical combination of ethinyl estradiol and drospirenone for use as a contraceptive | |
| AR031563A1 (en) | A PHARMACEUTICAL COMPOSITION FOR EMPLOYMENT IN THE TREATMENT OF MENOPAUSIC OR POSMENOPAUSIC DISORDERS OF STROGENS AND MEDROXIPROGESTERONE ACETATE, A PHARMACEUTICAL DOSAGE UNIT AND USE OF A CONJUGATED STRAGEN COMBINATION OF UTROGRAPHIC MANIFORM | |
| BR9808888A (en) | Dosage forms and method of improving male erectile dysfunction | |
| MA26843A1 (en) | NOVEL TOPICAL ESTRO-PROGESTIVE COMPOSITIONS WITH SYSTEMIC EFFECT | |
| CR7420A (en) | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE ONE OR VARIOUS STEROIDS, ONE OR VARIOUS COMPONENTS OF TETRAHIIDROPHOLATES AND VITAMIN B12 | |
| EP1429729A4 (en) | MIXED DOSAGE FORM COMPRISING A HYPOCHOLESTEROLEMIANT, A RENIN-ANGIOTENSIN INHIBITOR, AND ASPIRIN | |
| BR0009437A (en) | Pre-gelatinized starch in a controlled release formulation | |
| PE20051038A1 (en) | EXTENDED COMBINATION USE INCLUDING ESTROGENS AND PROGESTINES | |
| KR19990076685A (en) | Contraceptive methods and kits for female mammals comprising a combination of gestagen and estrogen | |
| PE20070208A1 (en) | ORAL CONTRACEPTION WITH TRIMEGESTONE | |
| PL402549A1 (en) | Vaginal pharmaceutical composition and use | |
| PE20070329A1 (en) | COMPOSITIONS WITH ESTROGENS AND THERAPEUTIC METHODS FOR THEIR USE | |
| NO327588B1 (en) | Pharmaceutical composition and composition comprising ethinylostradiol and drospirenone for use as a contraceptive | |
| AR036970A1 (en) | ANDROGENIC PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DEPRESSION | |
| AR045576A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING DROSPIRENONE AND ETHYLESTRADIOL | |
| Almen-Christensson et al. | Prevention of menstrual migraine with perimenstrual transdermal 17-β-estradiol: a randomized, placebo-controlled, double-blind crossover study | |
| PE20010665A1 (en) | A PHARMACEUTICAL COMPOSITION OF DROSPIRENONE AND ETHINYLESTRADIOL TO BE USED AS A CONTRACEPTIVE | |
| RU2000115313A (en) | GESTAGEN-ANTI-GESTAGEN RECEPTION DIAGRAMS | |
| BRPI0606297A2 (en) | solid peroral medicine for contraception | |
| AR047782A1 (en) | SOLID PHARMACEUTICAL COMPOSITIONS THAT INCLUDE A COMBINATION OF DROSPIRENONE, ETHYLYNESTRADIOL AND AN APPROPRIATE SURFACTING AGENT THAT PRESENTS A HOMOGENEITY OF CONTENT AND SPEED OF DISSOLVED INSURANCE FOR NON-MICRONIZED DRUG, PROCEDURE FOR PREPARATION OF USE | |
| CO5011086A1 (en) | BUDESONIDE ONLY OR IN COMBINATION WITH URSODESOXICOLIC ACID IN THE LIVER DISEASE THERAPY | |
| CO5160244A1 (en) | BIOADHESIVE TABLETS OF PROGRESSIVE HYDRATION | |
| AR035633A1 (en) | DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY | |
| Brackman | OESCLIM®: summary of tolerability and safety |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| MC | Annulment |